Nottingham Clinical Trials Unit
The University of Nottingham
University of Nottingham
  • Print
  

STROKE-CARE

 Tardis-cropped

 

Trial Name:  Safety and efficacy of intensive versus guideline antiplatelet therapy in high-risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised trial (TARDIS)

Chief Investigator:  Philip Bath, The University of Nottingham

Trial Description:  Nottingham Clinical Trials Unit collaborates with the Nottingham Stroke Trials Unit, led by Philip Bath, on several large scale multicentre trials.

The highest risk time for recurrence is immediately after stroke or transient ischaemic attack. Existing prevention strategies (such as antithrombotic drugs, lowering lipids or blood pressure lowering, and carotid endarterectomy) reduce, but do not abolish, further events. Dual antiplatelet therapy is superior to aspirin monotherapy. Triple antiplatelet therapy has already been shown to improve outcome for patients with coronary disease.

This international trial compares triple therapy (aspirin, dipyridamole and clopidogrel) with guideline antiplatelet therapy (combined aspirin and dipyridamole or clopidogrel) given for one month. Target sample size is 4,100 patients. The primary outcome is stroke severity at 90 days assessed using the modified Rankin Scale.

Contact: Lelia Duley

Funding:  British Heart Foundation and NIHR Health Technology Assessment

Status:  Recruiting

Publications:  2015-42

Further Information: tardis@nottingham.ac.uk 

 

 

 

 

 TICH-2


 Trial Name:  Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2)

Chief Investigator:  Nikola Sprigg, The University of Nottingham  

Trial Description: There is currently no effective treatment for stroke associated with intracerebral haemorrhage. Tranexamic acid is an antifibrinolytic drug, which reduces mortality in trauma patients who are bleeding, and is most effective if given early.

This trial is comparing intravenous tranexamic acid with placebo for patients who are within eight hours of acute primary intracerebral haemorrhagic stroke. Estimated sample size is 2,000 participants. Recruitment opened in March 2013.

Contact:  Lelia Duley

Funding:  NIHR Health Technology Assessment 

Status:  Recruiting

Further Information:  tich-2@nottingham.ac.uk

 

 

 

 

Trial Name:  Rapid Intervention with Glyceryl trinitrate in Hypersenstive stroke Trial-2 (RIGHT-2)

Chief Investigator:  Philip Bath, The University of Nottingham

Trial Description:  This trial is assessing the safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, and of the feasibility of a multicentre ambulance-based stroke trial. Total sample size is 850 participants. Recruitment opened in Septemer 2015. The primary outcome is death/dependence/independence: 7-level modified Rankin Scale (mRS) 90 days after stroke.

Contact:  Alan Montgomery

Funding:  British Heart Foundation

Status:  Recruiting

Further Information:   right-2@nottingham.ac.uk

 



UKCRC CTU Logo

Nottingham Clinical Trials Unit

General enquiries
Email: ctu@nottingham.ac.uk
Telephone: +44 (0)115 8231600